At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 209 enrolled
Drug / intervention
TAK-954 Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of 2 Dose Regimens of Intravenous TAK-954 for the Prophylaxis and Treatment of Postoperative Gastrointestinal Dysfunction in Patients Undergoing Large- and Small-Bowel Resection
In Brief
A Phase 2 clinical trial evaluating TAK-954 Placebo and TAK-954 for Postoperative Gastrointestinal Dysfunction. Completed, enrolled 209 participants across 25 sites in 2 countries.
Detailed Summary
The main aim of this study is to check for side effects from TAK-954 and whether it speeds up the recovery of gastrointestinal function after small-bowel or large-bowel resection surgery. Participants will be treated with TAK-954 before surgery and up to 10 days after surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesGermany, United States
CollaboratorsTakeda Development Center Americas, Inc.
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedFeb 2019
Enrollment StartMar 2019
Primary CompletionMay 2022
TodayJul 2026
First PostedFeb 1, 2019
Enrollment StartMar 7, 2019
Primary CompletionMay 27, 2022
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 7.4 years ago
Interventions
TAK-954 Placebodrug
TAK-954 placebo-matching intravenous infusion.
TAK-954drug
TAK-954 intravenous infusion.